Labetalol Pediatric Dose — Hypertensive Urgency
Labetalol is a combined alpha-1 and non-selective beta-adrenergic receptor antagonist that reduces systemic vascular resistance and cardiac output to lower blood pressure. It is commonly used in pediatric patients for the acute management of hypertensive urgency in the inpatient or emergency setting. Its dual adrenergic blockade provides a predictable, titratable antihypertensive effect suitable for children across a range of ages and weights.
Pediatric Dosing
The recommended dose for hypertensive urgency is 0.2 mg/kg per dose administered intravenously (IV), repeated every 1–2 hours as needed (PRN). The maximum single dose is 20 mg IV, regardless of weight.
- Dose: 0.2 mg/kg IV every 1–2 hours PRN
- Max single dose: 20 mg IV
Worked example: For a 20 kg child: 20 × 0.2 mg/kg = 4 mg IV per dose. For a 30 kg child: 30 × 0.2 mg/kg = 6 mg IV per dose. For patients weighing ≥100 kg, the 20 mg per-dose ceiling applies.
Indications and Clinical Context
Labetalol at this dose is indicated for pediatric hypertensive urgency — a clinical scenario characterized by significantly elevated blood pressure without acute end-organ damage. It is appropriate for inpatient use when parenteral therapy is required and the goal is a controlled, gradual reduction in blood pressure. Labetalol is frequently employed in the PICU and pediatric emergency department settings for conditions such as acute glomerulonephritis, renal parenchymal disease, or medication-related hypertension. Consult institutional protocols and nephrology or cardiology guidance for individualized management.
Unlike hypertensive emergency, urgency management does not mandate immediate blood pressure normalization; the intermittent PRN dosing schedule of labetalol aligns with this measured approach, allowing reassessment between doses.
Administration and Monitoring
Labetalol should be administered as a slow IV push over 2 minutes via a reliable peripheral or central venous line. The IO route is not routinely described for this indication; consult institutional protocol if IV access is unavailable. Repeat doses may be given every 1–2 hours as clinically indicated, not to exceed 20 mg per individual dose.
- Route: IV (slow push over ~2 minutes)
- Monitoring: Continuous heart rate and blood pressure monitoring during and after administration
- Key adverse effects: Bradycardia, hypotension, bronchospasm
- Contraindications: Reactive airway disease/asthma, cardiogenic shock, significant bradycardia, or decompensated heart failure
- Max dose: 20 mg per single IV dose — do not exceed regardless of weight
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.